This article was downloaded by: On: 22 January 2011 Access details: Access Details: Free Access Publisher Taylor & Francis Informa Ltd Registered in England and Wales Registered Number: 1072954 Registered office: Mortimer House, 37-41 Mortimer Street, London W1T 3JH, UK



Journal of Asian Natural Products Research

Publication details, including instructions for authors and subscription information: http://www.informaworld.com/smpp/title~content=t713454007

The synthesis of analogs of shuangkangsu, a novel natural cycloperoxide glucoside from *Lonicera japonica* Thunb

Yan-Bo Tang^a; Long-Jiang Huang^a; Di-Zao Li^a; Qing-Jian Zhang^a; Ruo-Yun Chen^a; De-Quan Yu^a ^a Key Laboratory of Bioactive Substances and Resources Utilization of Chinese Herbal Medicine, Ministry of Education, Peking Union Medical College, Institute of Materia Medica, Chinese Academy of Medical Sciences, Beijing, China

To cite this Article Tang, Yan-Bo , Huang, Long-Jiang , Li, Di-Zao , Zhang, Qing-Jian , Chen, Ruo-Yun and Yu, De-Quan(2009) 'The synthesis of analogs of shuangkangsu, a novel natural cycloperoxide glucoside from *Lonicera japonica* Thunb', Journal of Asian Natural Products Research, 11: 2, 172 – 176

To link to this Article: DOI: 10.1080/10286020802618985 URL: http://dx.doi.org/10.1080/10286020802618985

PLEASE SCROLL DOWN FOR ARTICLE

Full terms and conditions of use: http://www.informaworld.com/terms-and-conditions-of-access.pdf

This article may be used for research, teaching and private study purposes. Any substantial or systematic reproduction, re-distribution, re-selling, loan or sub-licensing, systematic supply or distribution in any form to anyone is expressly forbidden.

The publisher does not give any warranty express or implied or make any representation that the contents will be complete or accurate or up to date. The accuracy of any instructions, formulae and drug doses should be independently verified with primary sources. The publisher shall not be liable for any loss, actions, claims, proceedings, demand or costs or damages whatsoever or howsoever caused arising directly or indirectly in connection with or arising out of the use of this material.



The synthesis of analogs of shuangkangsu, a novel natural cycloperoxide glucoside from *Lonicera japonica* Thunb

Yan-Bo Tang, Long-Jiang Huang, Di-Zao Li, Qing-Jian Zhang, Ruo-Yun Chen and De-Quan Yu*

Key Laboratory of Bioactive Substances and Resources Utilization of Chinese Herbal Medicine, Ministry of Education, Peking Union Medical College, Institute of Materia Medica, Chinese Academy of Medical Sciences, Beijing, China

(Received 15 July 2008; final version received 28 October 2008)

Four novel optically pure cycloperoxide glucosides **9a**, **9b**, **10a**, and **10b**, analogs of shuangkangsu – a natural product with unusual skeleton and antivirus activity from the buds of *Lonicera japonica* Thunb, were firstly synthesized by employing peroxidation and glucosidation reactions from phthalaldehyde or 4,5-dichloro phthalaldehyde and glucose.

Keywords: shuangkangsu; cycloperoxide glucosides; shuangkangsu analogs; asymmetric synthesis

1. Introduction

Shuangkangsu (1) (Figure 1, [1]), a natural compound showed significant antivirus activities against influenza virus in chicken embryo and respiratory syncytial virus in cells, respectively, was isolated from the buds of Lonicera japonica Thunb, a famous traditional Chinese medicine that possesses functions of antipyretic and detoxical material and was used to treat influenza and pneumonia, etc. [2]. Shuangkangsu (1) is a novel cycloperoxide glucoside with unusual 2,3-dioxane-1,4-diol skeleton and glucosyl bond formed by hydroxyl of peroxide hemiacetal, which was found firstly in natural products. The unique molecular structure and significant antivirus activities render shuangkangsu a worthy target for chemical synthesis and structure modification. For initiating a synthetic program for shuangkangsu, we designed and synthesized analogs of shuangkangsu, and the structures of analogs are shown in Figure 1.

The retrosynthetic analysis that led to this approach is shown in Figure 2. Thus, retrosynthetic cleavage of the glucosyl bond followed by removal of the peroxide bond linkage led to phthalaldehyde.

2. Results and discussion

The synthetic route to compounds **9a**, **9b**, **10a**, and **10b**, analogs of shuangkangsu, is shown in Scheme 1.

4,5-Dichloro phthalaldehyde (2) or phthalaldehyde (3) reacted with H_2O_2 gave compound 4 or 5 in good yields. However, glucosylation of 4 or 5 was problematic. Firstly, peroxide 4 or 5 was not stable under acidic or basic conditions; next, according to previous reports [3–6], it was difficult to promote the yield of the reaction between compound 4 or 5 and glycosyl donors because of the low reactivity of hydroxyl of hemiacetal. So, it was better to select a suitable glucosylation method for 4 or 5. Glycosyl donor trichloroacetimidate (6) reacted with 4 or 5,

ISSN 1028-6020 print/ISSN 1477-2213 online © 2009 Taylor & Francis DOI: 10.1080/10286020802618985 http://www.informaworld.com

^{*}Corresponding author. Email: dqyu@imm.ac.cn



Figure 1. Structure of shuangkangsu and its analogs synthesized.

in this work, afforded compound **7** or **8** only in 5-8% yield under the usual condition using BF₃·Et₂O as the promoter. Additionally, when the glycosyl donor was changed to thioglycoside (**11**), which reacted with compound **5** on the condition of using AgOTf and NIS as the promoter, orthoester (**12**) was obtained in 10% yield. In the presence of BF₃·Et₂O, **12** rearranged to compound **8** (Scheme 2).

The result identified by LC-MS showed that compound 7 consisted of two compounds 7a and 7b (in the ratio with 1:1), which were separated by using HPLC. According to the previous study [1], substituents on C-1 and C-4 of shuangkangsu and its analogs preferred the *trans*-relative stereochemistry. The absolute configurations of 7a and 7b were determined to (1*S*, 4*S*) and (1*R*, 4*R*), respectively, by the comparison of cotton effect in their CD spectra with shuangkangsu's [1]. Similarly, 8a and 8b were obtained and their absolute configurations were determined to (1*S*, 4*S*) and (1*R*, 4*R*), respectively.

As mentioned above, this kind of peroxide was not stable under basic conditions, so common reagents, such as NaOCH₃, K₂CO₃, etc., which were used to remove the acetyl groups in sugar moiety to yield free glycoside, were not suitable for this work. Finally, dibutyltin oxide [7], a near-neutral reagent, was employed to react with **7a**, **7b**, **8a**, and **8b** in the presence of CH₃OH, succeeded to afford desired compounds **9a**, **9b**, **10a**, and **10b**, respectively.

3. Experimental

3.1 General experimental procedures

Melting points were determined on an XT_4 -100_X micro-melting apparatus and are uncorrected. Optical rotations were measured with PE-241 digital polarimeter. CD spectra were taken on JASCO J-725 spectro-photometer. The NMR spectra were recorded on Varian Mercury-300 spectrometer (300 MHz for ¹H and 75 MHz for ¹³C). HR-FAB-MS and HR-ESI-MS spectra were obtained on AutoSpec Ultima-TOF and AccuTOF CS mass spectrometer, respectively.

3.2 General procedures for the synthetic compounds

3.2.1 Compound 4

To a solution of 4,5-dichloro phthalaldehyde (0.63 g, 3.1 mmol) in 10 ml CH₃OH was added 30% H₂O₂ (0.35 g, 3.1 mmol). The reaction mixture was stirred at room temperature for 2 h and then concentrated. The residue was washed by CH₂Cl₂, **4** was obtained as white powder in 98% yield; mp 145–148°C; ¹H NMR (300 MHz, acetone- d_6) δ (ppm): 7.58 (s, 2H) and 5.98 (s, 2H); ¹³C NMR (75 MHz, CDCl₃) δ (ppm): 134.6, 132.3, 129.8, and 93.3.

3.2.2 Compounds 7a, 7b, 8a, and 8b

Compound **4** (0.3 g, 1.27 mmol), glycosyl trichloroacetimidate (**6**) (3 g, 6 mmol), and freshly activated 4 Å molecule sieve (2 g) were added to a 250 ml three-necked flask, which



Figure 2. Retrosynthetic analysis of analogs of shuangkangsu.



Scheme 1. Synthesis of analogs of shuangkangsu. Reagents and conditions: (a) H_2O_2 , CH_3OH , 2 h for 4 and 12 h for 5; (b) BF_3 · Et_2O , CH_2Cl_2/Et_2O , 0°C, 12 h and (c) dibutyltin oxide, CH_3OH , reflux, 4 h.

was purged with nitrogen. Dried CH_2Cl_2/Et_2O (100 ml, 1:1) were injected to the flask. The mixture was stirred at room temperature for 1 h, and then $BF_3 \cdot Et_2O$ (catalytic amount) was added at 0°C to the reaction mixture, which was allowed to stir at 0°C for another 12 h. The reaction mixture was diluted with CH_2Cl_2 (100 ml) and filtered through Celite. The filter cake was washed with CH_2Cl_2 and the combined filtrate was then washed with H_2O $(3 \times 50 \text{ ml})$, dried over anhydrous Na₂SO₄, filtered, and concentrated *in vacuo*. The residue was purified by silica gel column chromatography (gradient elution, PE/EtOAc = 6:1 to 3:1) followed by Sephadex LH-20 column chromatography (PE/CH₂Cl₂/CH₃OH = 5:5:1) to give **7** as white solid in 5% yield, which was separated into compound **7a** and its diastereomer **7b** by using HPLC (CH₃OH / H₂O = 60:40).



Scheme 2. Synthesis of compound **8** from thioglycoside. Reagents and conditions: (d) NIS/AgOTf, CH_2Cl_2/Et_2O , 0°C rt, 12 h and (e) BF₃·Et₂O, CH₂Cl₂, 10 h.

7a: White solid; $[\alpha]_D^{25} + 142$ (c = 0.01, acetone); ¹H NMR (300 MHz, acetone- d_6) δ (ppm): 7.49 (s, 2H), 6.13 (s, 2H), 5.40 (t, J = 9.0 Hz, 2H), 5.27 (d, J = 8.1 Hz, 2H), 5.05 (t, J = 9.0 Hz, 2H), 4.88 (d, J = 8.1 Hz, 2H), 4.32 (dd, J = 12.0, 2.4 Hz, 2H), 4.19 (dd, J = 12.3, 4.8 Hz, 2H), 4.09–4.05 (m, 2H), 2.09 (s, 6H), 2.04 (s, 6H), 2.02 (s, 6H), and 1.99 (s, 6H); ¹³C NMR (75 MHz, acetone- d_6) δ (ppm): 170.6, 170.2, 170.0, 169.7, 132.3, 130.9, 129.3, 98.0, 96.6, 74.1, 73.5, 72.2, 69.5, 63.0, 20.6, 20.5, and 20.4; HR-FAB-MS m/z: 919.1448 [M + Na]⁺ (calcd for C₃₆H₄₂O₂₂Cl₂Na, 919.1442); CD (acetone) $\Delta \varepsilon_{227 nm} + 16$ and $\Delta \varepsilon_{210 nm} - 7$.

7b: White solid; $[\alpha]_D^{25} - 105$ (*c* = 0.01, acetone); ¹H NMR (300 MHz, acetone-*d*₆) δ (ppm): 7.48 (s, 2H), 6.13 (s, 2H), 5.40 (t, *J* = 9.0 Hz, 2H), 5.27 (d, *J* = 8.1 Hz, 2H), 5.05 (t, *J* = 9.0 Hz, 2H), 4.88 (d, *J* = 8.1 Hz, 2H), 4.32 (dd, *J* = 12.0, 2.4 Hz, 2H), 4.19 (dd, *J* = 12.3, 4.8 Hz, 2H), 4.08-4.04 (m, 2H), 2.08 (s, 6H), 2.04 (s, 6H), 2.02 (s, 6H), and 1.99 (s, 6H); ¹³C NMR (75 MHz, acetone-*d*₆) δ (ppm): 170.6, 170.1, 169.9, 169.7, 132.4, 130.8, 129.3, 97.9, 96.6, 74.1, 73.5, 72.2, 69.5, 63.0, 20.6, 20.5, and 20.4; HR-FAB-MS *m*/*z*: 919.1436 [M + Na]⁺ (calcd for C₃₆H₄₂O₂₂Cl₂Na, 919.1442); CD (acetone) $\Delta \varepsilon_{226 \text{ nm}} - 20$ and $\Delta \varepsilon_{210 \text{ nm}} + 9$.

Compounds **8a** and **8b** were achieved by the same procedure.

8a: White solid; $[\alpha]_D^{25} + 170$ (*c* = 0.01, acetone); ¹H NMR (300 MHz, acetone-*d*₆) δ (ppm): 7.47–7.44 (m, 2H), 7.34–7.32 (m, 2H), 6.15 (s, 2H), 5.35 (t, *J* = 9.6 Hz, 2H), 5.30 (d, *J* = 8.1 Hz, 2H), 5.07 (t, *J* = 9.6 Hz, 2H), 4.97 (t, *J* = 8.1 Hz, 2H), 4.20 (dd, *J* = 12.0, 2.4 Hz, 2H), 4.11–4.07 (m, 2H), 2.04 (s, 6H), 2.00 (s, 6H), 1.97 (s, 6H), and 1.94 (s, 6H); ¹³C NMR (75 MHz, acetone-*d*₆) δ (ppm): 170.7, 170.2, 169.9, 169.7, 130.3, 130.0, 127.9, 97.8, 96.7, 73.4, 72.8, 71.7, 69.4, 62.6, 20.6, and 20.5; HR-ESI-MS *m*/*z*: 851.2263 [M + Na]⁺ (calcd for C₃₆H₄₄O₂₂Na, 851.2222); CD (acetone) $\Delta \varepsilon_{220 \text{ nm}} + 11$ and $\Delta \varepsilon_{210 \text{ nm}} - 5$.

 $\Delta \varepsilon_{220 \text{ nm}} + 11 \text{ and } \Delta \varepsilon_{210 \text{ nm}} - 5.$ **8b:** White solid; $[\alpha]_{\text{D}}^{25} - 120 \ (c = 0.02, \text{ acetone}); ^{1}\text{H NMR} (300 \text{ MHz, acetone-}d_{6}) \delta$ (ppm): 7.47–7.45 (m, 2H), 7.34–7.32 (m, 2H), 6.15 (s, 2H), 5.34 (t, J = 9.3 Hz, 2H), 5.30 (d, J = 8.1 Hz, 2H), 5.08 (t, J = 9.3 Hz, 2H), 4.97 (t, J = 8.1 Hz, 2H), 4.34 (dd, J = 12.0, 5.1 Hz, 2H), 4.20 (dd, J = 12.0, 2.4 Hz, 2H), 4.12–4.08 (m, 2H), 2.04 (s, 6H), 2.00 (s, 6H), 1.97 (s, 6H), and 1.94 (s, 6H); ¹³C NMR (75 MHz, acetone- d_6) δ (ppm): 170.6, 170.2, 170.0, 169.7, 130.2, 129.9, 127.9, 97.7, 96.7, 73.2, 72.1, 71.6, 69.3, 62.5, 20.5, and 20.4; HR-ESI-MS m/z: 851.2221 [M + Na]⁺ (calcd for C₃₆H₄₄O₂₂Na, 851.2222); CD (acetone) $\Delta \varepsilon_{219 \text{ nm}} - 11$ and $\Delta \varepsilon_{209 \text{ nm}} + 4$.

3.2.3 Compounds 9a, 9b, 10a, and 10b

To a solution of **7a** (50 mg, 0.06 mmol) in 5 ml CH₃OH, was added dibutyltin oxide (3 mg, 0.012 mmol). The reaction mixture was slightly refluxed for 4 h and then concentrated. The residue was purified by silica gel column chromatography (gradient elution, $CH_2Cl_2/CH_3OH = 20:1$ to 4:1) followed by Sephadex LH-20 column chromatography (PE/CH₂Cl₂/CH₃OH = 5:5:1) to afford **9a** as white solid in 19% yield.

Compounds **9b**, **10a**, and **10b** synthesized by the same procedure.

9a: White solid; mp 173–175°C; $[\alpha]_{D}^{25}$ + 173 (c = 0.005, H₂O); ¹H NMR (300 MHz, CD₃OD) δ (ppm): 7.48 (s, 2H), 5.86 (s, 2H), 4.41 (d, J = 7.5 Hz, 2H), 3.74– 3.61 (m, 8H), 3.32–3.28 (m, 2H), and 3.25– 3.22 (m, 2H); ¹³C NMR (75 MHz, CD₃OD) δ (ppm): 134.4, 133.3, 130.0, 98.2, 96.7, 78.0, 76.3, 74.9, 71.8, and 62.7; HR-FAB-MS *m/z*: 583.0581 [M + Na]⁺ (calcd for C₂₀H₂₆O₁₄ Cl₂Na, 583.0597); CD (H₂O) $\Delta \varepsilon_{240 \text{ nm}} + 4.5$ and $\Delta \varepsilon_{219 \text{ nm}} - 1.8$.

9b: White solid; mp $175-177^{\circ}$ C; $[\alpha]_{25}^{25} - 128$ (c = 0.005, H₂O); ¹H NMR (300 MHz, CD₃OD) δ (ppm): 7.48 (s, 2H), 5.86 (s, 2H), 4.42 (d, J = 8.4 Hz, 2H), 3.74– 3.70 (m, 4H), 3.65–3.61 (m, 4H), 3.32–3.28 (m, 2H), and 3.24–3.21 (m, 2H); ¹³C NMR (75 MHz, CD₃OD) δ (ppm): 134.4, 133.3, 130.0, 98.2, 96.7, 78.0, 76.3, 74.9, 71.8, and 62.7; HR-FAB-MS m/z; 583.0594 [M + Na]⁺ (calcd for $C_{20}H_{26}O_{14}Cl_2Na$, 583.0597); CD (H₂O) $\Delta \varepsilon_{239 \text{ nm}} - 5.1$ and $\Delta \varepsilon_{218 \text{ nm}} + 1.5$.

10a: White solid; mp 152–155°C; $[\alpha]_{D}^{25}$ + 138 (c = 0.005, H₂O); ¹H NMR (300 MHz, D₂O) δ (ppm): 7.36–7.32 (m, 2H), 7.28–7.23 (m, 2H), 5.76 (s, 2H), 4.75 (d, J = 6.9 Hz, 2H), 3.84–3.70 (m, 4H), 3.65– 3.61 (m, 4H), and 3.31–3.22 (m, 4H); ¹³C NMR (75 MHz, CD₃OD) δ (ppm): 132.6, 131.7, 127.2, 99.2, 96.7, 77.8, 75.8, 74.1, 71.8, and 61.7; HR-ESI-MS *m*/*z*: 515.1372 [M + Na]⁺ (calcd for C₂₀H₂₈O₁₄Na, 515.1377); CD (H₂O) $\Delta \varepsilon_{231 \text{ nm}}$ + 7.4 and $\Delta \varepsilon_{219 \text{ nm}}$ = 3.7.

10b: White solid; mp $151-153^{\circ}$ C; $[\alpha]_{D}^{25} - 172$ (c = 0.005, H₂O); ¹H NMR (300 MHz, D₂O) δ (ppm): 7.37-7.32 (m, 2H), 7.28-7.23 (m, 2H), 5.75 (s, 2H), 4.72 (d, J = 7.2 Hz, 2H), 3.85-3.61 (m, 8H), and 3.32-3.23 (m, 4H); ¹³C NMR (75 MHz, CD₃OD) δ (ppm): 132.7, 131.7, 127.3, 99.3, 96.6, 77.8, 75.8, 74.2, 71.9, and 61.8; HR-ESI-MS *m*/*z*: 515.1380 [M + Na]⁺ (calcd for C₂₀H₂₈O₁₄Na, 515.1377); CD (H₂O) $\Delta \varepsilon_{231 nm} - 8.1$ and $\Delta \varepsilon_{218 nm} + 3.8$.

3.2.4 Compound 12

Compound 5 (0.2 g, 1.2 mmol), thioglycoside 11 (1.88 g, 4.8 mmol), and freshly activated 4 Å molecule sieve (2 g) were added to a 250 ml three-necked flask, which was purged with nitrogen. Dried CH₂Cl₂/Et₂O (80 ml, 1:1) was injected to the flask. The mixture was stirred at room temperature for 1 h, and then NIS (1.35 g, 6 mmol) and a solution of AgOTf (0.12 g, 0.48 mmol) in 3 ml dried toluene were added at 0°C to the reaction mixture, which was allowed to stirred at room temperature overnight. The reaction mixture was filtered through Celite, and the combined filtrate was concentrated *in vacuo*. The residue was purified by silica gel column chromatography (PE/acetone = 3:1) twice and finally gained pure compound 12 as white solid in 10% yield; mp 128°C; ¹H NMR $(300 \text{ MHz}, \text{ acetone-} d_6) \delta \text{ (ppm)}: 7.41-7.37$ (m, 2H), 7.33-7.30 (m, 2H), 6.18 (s, 2H), 5.96 (d, J = 5.2 Hz, 2H), 5.16 (t, J = 2.8 Hz, 2H), 4.92 (dd, *J* = 2.8, 9.6 Hz, 2H), 4.57 (dd, J = 5.2, 2.8 Hz, 2H, 4.23 - 4.15 (m, 4H),4.07-4.03 (m, 2H), 2.07 (s, 6H), 2.06 (s, 6H), 2.02 (s, 6H), and 1.91 (s, 6H); ¹³C NMR $(75 \text{ MHz}, \text{ acetone-} d_6) \delta (\text{ppm}): 170.7, 170.1,$ 169.6, 131.4, 129.5, 127.6, 122.1, 97.9, 93.8, 73.9, 70.7, 69.1, 68.0, 63.9, 22.9, 20.7, 20.7, and 20.6; HR-ESI-MS m/z: 851.2212 $[M + Na]^+$ (calcd for $C_{36}H_{44}O_{22}Na$, 851.2222).

Acknowledgements

This research work was financially supported by National Natural Science Foundation of China (Grant No. 20372086).

References

- D.Q. Yu, R.Y. Chen, L.J. Huang, F.Z. Xie, D.S. Ming, K. Zhou, H.Y. Li, and K.M. Tong, *J. Asian Nat. Prod. Res.* **10**, 851 (2008).
- [2] The Eighth Chinese Pharmacopeia Commission, *Chinese Pharmacopeia 2005* (Chemical Industry Press, Beijing, 2006).
- [3] M. Nishizama, D.M. Garcia, Y. Noguchi, K. Komatsu, S. Hatakeyama, and H. Yamada, *Chem. Pharm. Bull.* 42, 2400 (1994).
- [4] K. Ramu and J.K. Baker, J. Med. Chem. 38, 1911 (1995).
- [5] A.J. Lin, L.Q. Li, S.L. Andersen, and D.L. Klayman, J. Med. Chem. 35, 1639 (1992).
- [6] P.M. O'Neill, F. Scheinmann, A.V. Stachulski, J.L. Maggs, and B.K. Park, *J. Med. Chem.* 44, 1467 (2001).
- [7] W. Li, H.M. Liu, and Q.D. You, Acta Chim. Sin. 61, 1516 (2003).